Cyclosporine treatment of psoriatic erythroderma complicated by bacterial sepsis.
Sprecher
E
E
Bergman
R
R
Friedman-Birnbaum
R
R
D017255:Acitretin / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D002437:Cefazolin / Q000627:therapeutic use; D002511:Cephalosporins / Q000627:therapeutic use; D016572:Cyclosporine / Q000627:therapeutic use*; D003873:Dermatitis, Exfoliative / Q000150:complications / Q000188:drug therapy*; D003879:Dermatologic Agents / Q000627:therapeutic use*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007641:Keratolytic Agents / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000150:complications / Q000188:drug therapy*; D018805:Sepsis / Q000382:microbiology; D013203:Staphylococcal Infections / Q000150:complications* / Q000188:drug therapy; D013290:Streptococcal Infections / Q000150:complications* / Q000188:drug therapy; D014640:Vancomycin / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D003879:Dermatologic Agents; D007166:Immunosuppressive Agents; D007641:Keratolytic Agents; D014640:Vancomycin; D016572:Cyclosporine; D002437:Cefazolin; D017255:Acitretin